



#28
KAY
10-22-02
1633/2
attachment

00766.000025

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

TETSUYOSHI ISHIWATA, ET AL.

Application No.: 09/129,603

Filed: August 5, 1998

For: DNA ENCODING IgA
NEPHROPATHY INDICATING
PROTEIN

) Examiner: Karen A. Lacourciere

) Group Art Unit: 1635

RECEIVED

OCT 18 2002

) October 8, 2002

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449. Copies of the listed documents are also enclosed.

STATEMENT UNDER 37 C.F.R. § 1.97(e)

Each item of information in this information disclosure statement was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of this Statement.

10/16/2002 SSESHE1 00000115 09129603

01 FC:1806

180.00 OP


CONCLUSION

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

Pursuant to the provisions of 37 C.F.R. § 1.97(d)(3), a check in the amount of \$180.00 is enclosed. Any deficiencies incurred in connection herewith may be charged to Deposit Account No. 06-1205.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,


Attorney for Applicants
Lawrence S. Perry
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200